India, Oct. 3 -- Aarti Drugs' recent expansion goes beyond just increasing manufacturing capacity. The company has invested approximately Rs600 crore in various projects aimed at enhancing capacity, backward integration, and asset utilization. The key question is how much of the benefit will show up as higher reported revenue versus lower input costs and improved margins from captive consumption.

Aarti Drugs was trading around Rs415 per share, with a market capitalization of roughly Rs3,788 crore and a P/E of around 20x. The stock's 52-week range was approximately Rs319-Rs534.

Sayakha Creates A Different Payoff The Sayakha facility is particularly important because it produces di-, mono- and tri-methylamines and their derivatives, whic...